TrialArthritis research & therapy2022

CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production.

Rajula Gaur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.